Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 11 - 29 tags : Drug save search
Certara Announces Update of D360™ Scientific Informatics SoftwareNew capabilities increase efficiency in analyzing and developing small molecules and biologic drugs
Published: 2021-11-29 (Crawled : 23:00) - biospace.com/
CERT | $16.435 -1.76% -1.79% 420K
|
|
| O: 0.47%
H: 1.86%
C: 0.71%
software drug
Adial Pharmaceuticals Announces Positive Pre-Clinical Data for PNV2 as a Drug Candidate for Triple Negative Breast CancerPNV2 demonstrates reduction of metastases in animal model
Published: 2021-11-29 (Crawled : 15:00) - biospace.com/
ADIL | News | $1.72 1.18% 1.16% 140K
|
Health Technology
|
| O: -0.35%
H: 1.76%
C: -9.86%
drug pre-clinical positive cancer negative breast cancer preclinical
Celularity Announces FDA Clearance of Investigational New Drug Application (IND) for Natural Killer Cell Therapy CYNK-101 in First-line Advanced Her2/neu Positive Gastric and Gastroesophageal Junction Cancer
Published: 2021-11-29 (Crawled : 14:30) - biospace.com/
CELU | News 4 | $3.385 5.45% 5.17% 36K
|
|
| O: 1.48%
H: 2.19%
C: -2.19%
new drug fda clearance application drug fda clearance positive therapy cancer her2- her2
Viracta Therapeutics Announces Orphan Drug Designation Granted by FDA for its All-Oral Combination of Nanatinostat and Valganciclovir (Nana-val) for the Treatment of Epstein Barr Virus-Positive Diffuse Large B-cell Lymphoma
Published: 2021-11-29 (Crawled : 14:00) - biospace.com/
VIRX | $0.8367 -1.31% -1.33% 55K
|
Manufacturing
|
| O: 3.57%
H: 4.21%
C: -12.45%
treatment fda drug granted therapeutics orphan drug positive t-cell designation
G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with the Antibody-Drug Conjugate (ADC)
Published: 2021-11-29 (Crawled : 13:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
GTHX | $3.98 -5.01% -5.28% 340K
|
Health Technology
|
| O: 0.75%
H: 0.82%
C: -6.28%
phase 2 trilaciclib antibody drug trial therapeutics
Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
Published: 2021-11-29 (Crawled : 13:00) - globenewswire.com
VRCA | $6.8 -0.73% -0.74% 110K
|
Health Technology
|
| O: -5.72%
H: 5.02%
C: -0.09%
molluscum new drug treatment application drug submission resubmission
Immunome Announces Submission of an Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19
Published: 2021-11-29 (Crawled : 12:30) - biospace.com/
IMNM | $14.28 -2.59% -2.66% 560K
|
Health Technology
|
| O: 7.88%
H: 13.26%
C: 12.55%
covid new drug treatment application drug submission
Bristol Myers Squibb’s Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency
Published: 2021-11-29 (Crawled : 12:30) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.24%
H: 0.0%
C: 0.0%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: -1.18%
H: 1.16%
C: 0.49%
psoriasis food treatment europe application drug plague
G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with the Antibody-Drug Conjugate (ADC), Trodelvy® (Sacituzumab Govitecan-Hziy)
Published: 2021-11-29 (Crawled : 12:00) - globenewswire.com
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
GTHX | $3.98 -5.01% -5.28% 340K
|
Health Technology
|
| O: 0.75%
H: 0.82%
C: -6.28%
trodelvy phase 2 trilaciclib antibody drug trial therapeutics
Fennec Pharmaceuticals Expects to Receive Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors
Published: 2021-11-29 (Crawled : 12:00) - biospace.com/
FENC M | $10.5 -3.05% -3.14% 100K
|
Health Technology
|
| O: -50.05%
H: 0.0%
C: 0.0%
new drug fda solid tumors application drug
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.